Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer Malin

Showing results (11-20 of 51) with videos related to

Pageof 6
Sort By:
American Journal of Clinical Oncology|March 8, 2011
Comparative effectiveness of filgrastim, pegfilgrastim, and sargramostim as prophylaxis against hospitalization for neutropenic complications in patients with cancer receiving chemotherapyDerek Weycker, Jennifer Malin, Rich Barron, et al.
Cancer Investigation|October 27, 2020
Real-World Outcomes and Value of First-Line Therapy for Metastatic Non-Small Cell Lung Cancer<sup>†</sup>Stacey DaCosta Byfield, Benjamin Chastek, Stephanie Korrer, et al.
Clinical Therapeutics|June 23, 2009
Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: a retrospective cohort studyDerek Weycker, Jennifer Malin, John Kim, et al.
Journal of Managed Care Pharmacy : JMCP|May 18, 2007
Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3-4 week chemotherapy regimens in community oncology practicesVicki A Morrison, Mitchell Wong, Dawn Hershman, et al.
Cancer|March 29, 2002
Outpatient cancer drug costs: changes, drivers, and the futureR J Halbert, Carol Zaher, Sally Wade, et al.
Drug Safety|May 23, 2012
Novel adverse events of bevacizumab in the US FDA adverse event reporting system database: a disproportionality analysisBehrooz K Shamloo, Pankdeep Chhabra, Andrew N Freedman, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 22, 2015
NCCN Roundtable:Value-Based Decision-Making at the BedsidePeter B Bach, Stephen B Edge, Linda House, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|July 11, 2007
Measuring health-related quality of life and neutropenia-specific concerns among older adults undergoing chemotherapy: validation of the Functional Assessment of Cancer Therapy-Neutropenia (FACT-N)Lynne I Wagner, Jennifer L Beaumont, Beiying Ding, et al.
The American Journal of Managed Care|May 31, 2017
Physician variation in lung cancer treatment at the end of lifeJonas B Green, Martin F Shapiro, Susan L Ettner, et al.
Journal of the National Cancer Institute|November 12, 2009
Patterns of use and risks associated with erythropoiesis-stimulating agents among Medicare patients with cancerDawn L Hershman, Donna L Buono, Jennifer Malin, et al.
Pageof 6

Showing results (11-20 of 51) with videos related to

Sort By:
Pageof 6
American Journal of Clinical Oncology|March 8, 2011
Comparative effectiveness of filgrastim, pegfilgrastim, and sargramostim as prophylaxis against hospitalization for neutropenic complications in patients with cancer receiving chemotherapyDerek Weycker, Jennifer Malin, Rich Barron, et al.
Cancer Investigation|October 27, 2020
Real-World Outcomes and Value of First-Line Therapy for Metastatic Non-Small Cell Lung Cancer<sup>†</sup>Stacey DaCosta Byfield, Benjamin Chastek, Stephanie Korrer, et al.
Clinical Therapeutics|June 23, 2009
Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: a retrospective cohort studyDerek Weycker, Jennifer Malin, John Kim, et al.
Journal of Managed Care Pharmacy : JMCP|May 18, 2007
Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3-4 week chemotherapy regimens in community oncology practicesVicki A Morrison, Mitchell Wong, Dawn Hershman, et al.
Cancer|March 29, 2002
Outpatient cancer drug costs: changes, drivers, and the futureR J Halbert, Carol Zaher, Sally Wade, et al.
Drug Safety|May 23, 2012
Novel adverse events of bevacizumab in the US FDA adverse event reporting system database: a disproportionality analysisBehrooz K Shamloo, Pankdeep Chhabra, Andrew N Freedman, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 22, 2015
NCCN Roundtable:Value-Based Decision-Making at the BedsidePeter B Bach, Stephen B Edge, Linda House, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|July 11, 2007
Measuring health-related quality of life and neutropenia-specific concerns among older adults undergoing chemotherapy: validation of the Functional Assessment of Cancer Therapy-Neutropenia (FACT-N)Lynne I Wagner, Jennifer L Beaumont, Beiying Ding, et al.
The American Journal of Managed Care|May 31, 2017
Physician variation in lung cancer treatment at the end of lifeJonas B Green, Martin F Shapiro, Susan L Ettner, et al.
Journal of the National Cancer Institute|November 12, 2009
Patterns of use and risks associated with erythropoiesis-stimulating agents among Medicare patients with cancerDawn L Hershman, Donna L Buono, Jennifer Malin, et al.
Pageof 6